David Dai

Q: What is David Dai's success rate?

David Dai currently has a success rate of 87.47901015250537.

Q: What is the average return of David Dai's calls?

Their stock ratings have generated an average return of 32.73715749407149.

UBS | Healthcare

David Dai is an analyst from UBS specializing in the Healthcare sector. Ranked #786 out of 4773 analysts, they have issued 27 stock ratings with a success rate of 87.48% and an average return of 32.74%.

David Dai has a well-established track record, with 27 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 87.48% and an average return of 32.74%, underscoring their expertise and ability to identify winning opportunities for investors.

#786

Out of 4773

Total Ratings

+87.48%

Success Rate

+32.74%

Average Return

Recent Ratings Analysis

SNDX

Buy

Aug 21, 2026

Target

$33.00

Current

$18.18

Performance

-7.48%

David Dai rated SNDX as Buy on Aug 21, 2026, setting a price target of 33. The stock has underperformed, dropping 7.48% despite the bullish target of 33.

IOVA

Hold

Aug 20, 2026

Target

$7.00

Current

$8.60

Performance

-4.34%

On Aug 20, 2026, IOVA was given a Neutral rating by David Dai, with a target price of 7. Market indecision, reflected in sideways trading near 8.6, supported the cautious call.

NRIX

Buy

Jul 22, 2026

Target

$31.00

Current

$25.10

Performance

6.36%

NRIX received a Buy rating from David Dai on Jul 22, 2026, aiming for 31. Momentum has favored the Buy call, with shares climbing from 25.1 to 25.1, rewarding those who trusted the recommendation.

ASML

Buy

Jul 06, 2026

Target

$2623.00

Current

$1698.30

Performance

-6.95%

On Jul 06, 2026, David Dai published a Outperform outlook on ASML, with a target of 2623. Market action contradicted the Buy thesis, as shares slipped to 1698.3.

NUVL

Hold

Jun 10, 2026

Target

$124.00

Current

$123.96

Performance

0.49%

David Dai on Jun 10, 2026 assigned NUVL a Neutral rating, with a price target of 124. The Hold stance reflected consolidation, as shares held near 123.96.

CLDX

Buy

Jun 10, 2026

Target

$45.00

Current

$36.90

Performance

25.72%

On Jun 10, 2026, David Dai reaffirmed CLDX with a Buy rating, targeting 45. The recommendation was supported by strong follow-through as the stock rose from 36.9 to 36.9.

BNTX

Buy

May 27, 2026

Target

$135.00

Current

$96.73

Performance

4.01%

BNTX was rated Buy by David Dai on May 27, 2026, with a price objective of 135. The stock is in a wait-and-see zone, leaving the Buy case open-ended.

ARM

Buy

May 18, 2026

Target

$300.00

Current

$264.79

Performance

23.09%

On May 18, 2026, David Dai initiated coverage on ARM with a Outperform rating and target of 300. The stock’s climb of 23.09% since the call highlights the foresight in the rating.

JANX

Hold

Apr 15, 2026

Target

$15.00

Current

$17.10

Performance

—

David Dai issued a Neutral recommendation for JANX on Apr 15, 2026, price target set at 15. The rating was appropriate for a consolidating market trading near 17.1.

JSPR

Hold

Mar 23, 2026

Target

$1.50

Current

$0.66

Performance

-44.51%

On Mar 23, 2026, JSPR was evaluated by David Dai, who gave a Neutral rating and target of 1.5. The Hold call avoided chasing into subsequent weakness of 44.51%.

CATX

Buy

Mar 18, 2026

Target

$8.00

Current

$2.81

Performance

-42.18%

David Dai rated CATX as Buy on Mar 18, 2026, setting a price target of 8. The stock has underperformed, dropping 42.18% despite the bullish target of 8.

SONY

Hold

Mar 17, 2026

Target

$22.00

Current

$23.90

Performance

14.24%

On Mar 17, 2026, SONY was given a Market Perform rating by David Dai, with a target price of 22. The stock rallied from 23.9 to 23.9 after the Hold rating, surprising to the upside.

KURA

Buy

Mar 13, 2026

Target

$15.00

Current

$11.39

Performance

31.68%

KURA received a Buy rating from David Dai on Mar 13, 2026, aiming for 15. Momentum has favored the Buy call, with shares climbing from 11.39 to 11.39, rewarding those who trusted the recommendation.

KYMR

Buy

Mar 03, 2026

Target

$128.00

Current

$114.96

Performance

33.13%

On Mar 03, 2026, David Dai published a Buy outlook on KYMR, with a target of 128. Shares gained 33.13%, underscoring the accuracy of the bullish outlook toward 128.

MRUS

Hold

Sep 30, 2025

Target

$97.00

Current

$90.00

Performance

-4.41%

David Dai on Sep 30, 2025 assigned MRUS a Neutral rating, with a price target of 97. The Hold stance reflected consolidation, as shares held near 90.

TLX

Buy

Sep 23, 2025

Target

$20.00

Current

$11.29

Performance

3.29%

On Sep 23, 2025, David Dai reaffirmed TLX with a Buy rating, targeting 20. Market indecision has kept the 20 target in a holding pattern.

SMMT

Buy

Jul 01, 2025

Target

$30.00

Current

$17.55

Performance

-17.22%

SMMT was rated Buy by David Dai on Jul 01, 2025, with a price objective of 30. This case shows how bullish projections can fail, with the stock now below 17.55.

Frequency Asked Questions

Who is David Dai?

David Dai is an analyst from UBS specializing in the Healthcare sector.

What is David Dai's success rate?

David Dai currently has a success rate of +87.48%.

How many ratings has David Dai issued?

David Dai has issued 27 stock ratings so far.

What is the average return of David Dai's calls?

Their stock ratings have generated an average return of +32.74%.

What is David Dai's ranking?

David Dai is ranked #786 out of 4773 analysts.

What types of ratings does David Dai give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow David Dai?

You can follow David Dai by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by David Dai?

Their latest rating was a Buy on SNDX issued on 2026-08-21.